177-lutetium-PSMA and 225-actinium-PSMA or Peptide Receptor Treatments

177-lutetium-PSMA and 225-actinium-PSMA in the treatment of metastatic prostate cancer

In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA* drug therapy in the treatment of  advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects. 225-actinium-PSMA drug was used in 2021 for the first time.

Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA or 225-actinium-PSMA uptake occurs in the metastases.

177-lutetium-PSMA and 225-actinium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA) or approximately every 8 week (225-actinium-PSMA).

The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.

*177-lutetium-PSMA och 225-actinium-PSMA are still experimental treatments, and have a special permission for compassionate use by the Finnish Medicines Agency (Fimea). The international randomised controlled trials are also in their third phase, after which official and more detailed Current Care Guidelines can probably be issued for the cancer cases selected for treatment. However, some results were already presented in October’s ESMO2018 conference, according to which the dose escalation study had shown that even a dose three times larger than that proved effective at Docrates was found safe and well tolerated without the appearance of the toxicity that restricts the dosage.
The VISION study results** were presented in ESMO2021 conference: the results showed that treatment with 177-lutetium-PSMA significantly improved overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.

**Publiced in NEJM September 2021

Read more

Docrates Cancer Center has appointed Anna-Sofia Malmi as Marketing and Communications Director

Anna-Sofia Malmi, M.Sc (Education), has been appointed as Marketing and Communications Director at Docrates Cancer Center and a member of...

Read more

Accurate information on aggressiveness and tumor staging form the basis for prostate cancer treatment

In western countries, prostate cancer is the most common cancer type in men. In its early stages, it is often...

Read more

Should low-risk prostate cancer be left to active monitoring?

Active treatment vs. monitoring of localised low-risk prostate cancer has long been a contested topic. According to the results of...

Read more

Docrates uses the newest drug therapies for breast cancer

New cancer drugs are being developed all the time, and new uses are being found for drugs already in use....

Read more

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
358 10 773 2010

Contact us!

Mon-Thu 8 am-6 pm, Fri 8 am-4 pm (GMT +3)